{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"30","value":"29"},{"groupId":"OG001","lowerLimit":"1","upperLimit":"30","value":"15"},{"groupId":"OG002","lowerLimit":"1","upperLimit":"48","value":"24"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"description":"Overall survival is the time in months from start of study treatment to date of death due to any cause.","dispersionType":"Full Range","groups":[{"description":"Patients receive Akt/ERK inhibitor ONC201 125 mg PO on day 1 of every cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"ONC201 125 mg"},{"description":"Patients receive Akt/ERK inhibitor ONC201 250 mg PO every 7 days. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"ONC201 250 mg"},{"description":"Patients receive Akt/ERK inhibitor ONC201 625 mg PO every 7 days. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG002","title":"ONC201 625 mg"}],"paramType":"MEDIAN","populationDescription":"Overall survival for each arm measured in months","reportingStatus":"POSTED","timeFrame":"every 3 months for 1 year, then every 6 months, up to 3 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}